Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | GABRA1 | P14867 | 3/20 | 0.32 |
| ▸ | GABRG2 | P18507 | 3/20 | 0.32 |
| ▸ | GABRB3 | P28472 | 3/20 | 0.32 |
| ▸ | GABRA5 | P31644 | 3/20 | 0.32 |
| ▸ | GABRA3 | P34903 | 3/20 | 0.32 |
| ▸ | IGF1R | P08069 | 2/20 | 0.32 |
| ▸ | CDK2 | P24941 | 1/20 | 0.31 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.30 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.30 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3554797 | 0.84 | ABL1 (0.33) | KDM4EGABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL2200361 | 0.84 | KDM4E (0.42) | KDM4EGABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL3558571 | 0.84 | IGF1R (0.33) | KDM4EGABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL2198656 | 0.84 | BRD4 (0.35) | KDM4EGABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL3552402 | 0.84 | GABRA1 (0.38) | KDM4EGABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL2200414 | 0.84 | BRD4 (0.38) | KDM4EGABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL3557071 | 0.82 | MKNK1 (0.36) | KDM4EGABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL3554819 | 0.82 | KDM4E (0.32) | KDM4EGABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL3553100 | 0.82 | KDM4E (0.39) | KDM4EIGF1RCDK2 | |
| SCHEMBL2197951 | 0.81 | GABRA1 (0.32) | KDM4EGABRA1GABRG2GABRB3GABRA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7977336-B2 | Aminopyrimidine derivatives as PLK1 inhibitors | BANYU PHARMACEUTICAL CO. LTD (JP) | 2011-07-12 | — | — | US | disclosed |
| EP-2114942-A1 | NOVEL AMINOPYRIMIDINE DERIVATIVES AS PLK1 INHIBITORS | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2009-11-11 | — | — | EP | disclosed |
| EP-2116543-A1 | NOVEL AMINOPYRIMIDINE DERIVATIVE AS PLK1 INHIBITOR | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2009-11-11 | — | — | EP | disclosed |
| US-20080305081-A1 | Novel aminopyrimidine derivatives as PLK1 inhibitors | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2008-12-11 | — | — | US | disclosed |
| WO-2008081910-A1 | NOVEL AMINOPYRIMIDINE DERIVATIVES AS PLK1 INHIBITORS | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2008-07-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080305081-A1 | Novel aminopyrimidine derivatives as PLK1 inhibitors | PLK1, AURKA, CDK1 | KDM4E 1233/4885GABRA1 4313/4885GABRG2 4414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.